Literature DB >> 31192152

Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2019        PMID： 31192152      PMCID： PMC6547263          DOI： 10.1159/000500143

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  25 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 2.  Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Authors:  Barbara Merelli; Daniela Massi; Laura Cattaneo; Mario Mandalà
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-28       Impact factor: 6.312

Review 3.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

4.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Authors:  Lauren C Harshman; Charles G Drake; Jennifer A Wargo; Padmanee Sharma; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2014-08       Impact factor: 11.151

6.  Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Authors:  Qiang Gao; Xiao-Ying Wang; Shuang-Jian Qiu; Ichiro Yamato; Masayuki Sho; Yoshiyuki Nakajima; Jian Zhou; Bai-Zhou Li; Ying-Hong Shi; Yong-Sheng Xiao; Yang Xu; Jia Fan
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

7.  Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

Authors:  Raoul A Droeser; Christian Hirt; Carsten T Viehl; Daniel M Frey; Christian Nebiker; Xaver Huber; Inti Zlobec; Serenella Eppenberger-Castori; Alexander Tzankov; Raffaele Rosso; Markus Zuber; Manuele Giuseppe Muraro; Francesca Amicarella; Eleonora Cremonesi; Michael Heberer; Giandomenica Iezzi; Alessandro Lugli; Luigi Terracciano; Giuseppe Sconocchia; Daniel Oertli; Giulio C Spagnoli; Luigi Tornillo
Journal:  Eur J Cancer       Date:  2013-03-13       Impact factor: 9.162

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 10.  Control of the immune response by pro-angiogenic factors.

Authors:  Thibault Voron; Elie Marcheteau; Simon Pernot; Orianne Colussi; Eric Tartour; Julien Taieb; Magali Terme
Journal:  Front Oncol       Date:  2014-04-02       Impact factor: 6.244
View more
  11 in total

1.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

Review 2.  Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Authors:  Zuyuan Lin; Di Lu; Xuyong Wei; Jianguo Wang; Xiao Xu
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

3.  A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

Review 4.  Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

Review 5.  Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.

Authors:  Jiting Wang; Jun Li; Guiju Tang; Yuan Tian; Song Su; Yaling Li
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

Review 6.  Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.

Authors:  Rui Xing; Jinping Gao; Qi Cui; Qian Wang
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

7.  Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.

Authors:  Sirish Dharmapuri; Umut Özbek; Jung-Yi Lin; Max Sung; Myron Schwartz; Andrea D Branch; Celina Ang
Journal:  Cancer Med       Date:  2020-05-18       Impact factor: 4.452

Review 8.  Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

Authors:  Hye Won Lee; Kyung Joo Cho; Jun Yong Park
Journal:  Immune Netw       Date:  2020-02-17       Impact factor: 6.303

Review 9.  Emerging agents and regimens for hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Hui-Chuan Sun
Journal:  J Hematol Oncol       Date:  2019-10-26       Impact factor: 17.388

10.  Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Authors:  Shixue Chen; Ziwei Huang; Wangping Jia; Haitao Tao; Sujie Zhang; Junxun Ma; Zhefeng Liu; Jinliang Wang; Lijie Wang; Pengfei Cui; Zhibo Zhang; Di Huang; Zhaozhen Wu; Xuan Zheng; Yi Hu
Journal:  J Hepatocell Carcinoma       Date:  2020-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.